Precision BioSciences Reports Breakthrough Hepatitis B Data and Advances DMD Trial
Event summary
- Precision BioSciences reported a 1-log reduction in cccDNA-derived transcripts in a hepatitis B patient after two doses of PBGENE-HBV.
- The company presented preclinical data at ASGCT showing higher efficacy of PBGENE-DMD in early-juvenile mice compared to late-juvenile mice.
- Precision received a $7.5 million clinical milestone payment from TG Therapeutics for the azer-cel program in progressive multiple sclerosis.
- The company reported $112.4 million in cash as of June 30, 2026, with an expected runway through 2028.
The big picture
Precision BioSciences' breakthrough in targeting cccDNA in hepatitis B positions it as a leader in gene editing therapies. The company's advancements in DMD and partnerships with TG Therapeutics and iECURE highlight its strategic focus on high-impact genetic diseases. With a clear financial runway, Precision is well-positioned to capitalize on the growing demand for curative gene therapies.
What we're watching
- Clinical Validation
- Whether the sustained loss of pgRNA in hepatitis B patients will translate into long-term viral cure.
- Trial Execution
- The pace at which Precision can enroll patients and collect additional data for the ELIMINATE-B trial.
- Financial Sustainability
- How Precision will manage its cash runway to achieve key milestones through 2028.
Related topics